TICKERNERD
Menu
PULMPULMHealthcare · Biotechnology

PULM Stock Forecast: Pulmatrix, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.42
+0.35% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$5.1M
Ticker Nerd rank
48/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$1.0M
Net income−$1.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.1%
1M
−6.6%
YTD
−36.3%
1Y
−71.3%
From 52W high
−71.3%
From 52W low
+19.3%
$1.19
$4.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PULM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmatrix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Growth
91
Issuance
75
Volatility
71
Accruals
50
Value
34
Quality
33
Revisions
25
Momentum
8

Size (94): Smaller than most of the companies we track.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PULM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PULM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26PULM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Aug 2023HC Wainwright & Co.ReiteratesBuy$10
15 May 2023HC Wainwright & Co.ReiteratesBuy—
7 Feb 2023HC Wainwright & Co.ReiteratesBuy—
30 Mar 2022HC Wainwright & Co.MaintainsBuy—
13 Apr 2021HC Wainwright & Co.MaintainsBuy$10 → $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PULM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PULM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Pulmatrix, Inc. returned −71.3% against +12.4% for the S&P 500, dividends included.

PULM vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PULMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PULM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Pulmatrix, Inc. (PULM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
3.2×

Cheaper than 28% of US stocks

EV / EBITDA
−0.7×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.3%

Higher than 13% of US stocks

Return on assets
−54.7%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pulmatrix, Inc. (PULM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulmatrix, Inc. has a market value of $5.1M and an enterprise value of $3.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$4.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$3.9M.

  • Shares outstanding: 3.7M.

  • Trailing P/E: −1.0×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pulmatrix, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

PULM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PULMPulmatrix, Inc.$5.1M48
IMNNImunon, Inc.$5.1M23
SNTISenti Biosciences Holdings, Inc.$5.1M42
PCSAProcessa Pharmaceuticals, Inc.$5.3M24
CDIOCardio Diagnostics Holdings, Inc.$4.9M20
LGVNLongeveron, Inc.$5.3M35
XBIOXenetic Biosciences, Inc.$4.8M31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulmatrix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PULM news & analysis

Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

GlobeNewsWire · 30 Oct 2026neutral

Eos SENOLYTIX reported interim results from an externally tested study in super-aged rats, showing preserved motor performance and reduced fat mass with PTC-2105. The findings were described as consistent with prior aged-mouse results and supportive of IND-enabling development ahead of planned first-in-human trials.

Why it matters — The item concerns Eos SENOLYTIX and reports no direct development or operating update for Pulmatrix.

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse

GlobeNewsWire · 22 Oct 2026neutral

Eos SENOLYTIX presented preclinical data reporting that once-weekly PTC-2105 increased overall survival versus saline in naturally aged mice. The company also launched “Team Speedy,” a webpage following a treated mouse reported to be more than 167 weeks old.

Why it matters — The item concerns another biotechnology company’s preclinical research and does not report a development involving Pulmatrix.

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

GlobeNewsWire · 22 Sept 2026neutral

Eos SENOLYTIX announced that founder and CEO Kevin Slawin, M.D., will deliver an industry keynote on mitochondrial-targeted geropeptide medicine at the 17th World Congress on Targeting Mitochondria. The company is advancing its lead candidate MitoXcel geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity, and anticipates closing its merger with Pulmatrix, Inc. in Q4 subject to customary closing conditions.

Why it matters — A Pulmatrix watcher would care because Eos states it anticipates closing its merger with Pulmatrix in Q4, which would combine the two companies subject to customary closing conditions.

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

PRNewsWire · 13 Aug 2026neutral

Pulmatrix announced its second quarter 2026 financial results and provided a corporate update on its merger agreement with Eos SENOLYTIX. A Form S-4 related to the announced merger was filed.

Why it matters — PULM watchers would care because the filing and update signal progress in the company's announced merger with Eos SENOLYTIX alongside its quarterly results.

FAQ

Frequently asked questions about PULM stock

Is PULM stock a buy right now?

Of the 1 analysts covering Pulmatrix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmatrix, Inc. 48 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PULM?

As at 31 Oct 2026, Pulmatrix, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the PULM stock forecast for 2030?

No analyst covering Pulmatrix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PULM are extrapolating price history, which says nothing about the business.

How has PULM stock performed over the past year?

Pulmatrix, Inc. returned -71.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmatrix, Inc. do?

Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine.

What is the latest news on PULM?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study". Eos SENOLYTIX reported interim results from an externally tested study in super-aged rats, showing preserved motor performance and reduced fat mass with PTC-2105. The findings were described as consistent with prior aged-mouse results and supportive of IND-enabling development ahead of planned first-in-human trials.

Company

About Pulmatrix, Inc.

Pulmatrix Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases and migraine. The company’s work centers on its proprietary iSPERSE engineered dry powder delivery platform, which is designed to deliver small and large molecule drugs directly to the lungs for local or systemic use. Pulmatrix’s current product candidates address serious conditions with unmet medical needs, including chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, and acute migraine. Its research and development activity is concentrated on creating inhaled formulations that may improve drug delivery efficiency and patient tolerability. Based in Framingham, Massachusetts, Pulmatrix operates within the biotechnology and pharmaceutical sectors, where it contributes to the development of specialized pulmonary-delivered therapeutics.

CEO Mr. Peter Ludlum CMA, MBA · 2 employees · United States · https://www.pulmatrix.com